CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CVB - CURVEBEAM AI LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.185

05 Sep
2024

0.000

OPEN

$0.20

0.000

HIGH

$0.20

239,913

LOW

$0.19

TARGET
$0.26 40.5% upside
FNARENA'S MARKET CONSENSUS FORECASTS
CVB: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A - 6.7 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

05/09/2024

1

Speculative Buy

$0.26

40.54%

The 10 purchase orders for new devices in the 4Q of FY24 are yet to be delivered and installed, resulting in a material miss for Curvebeam AI's FY24 revenue against Bell Potter's forecast.

Sales of the HiRise (foot and ankle) in FY24 were well below management's expectation, but validation of the Enhanced HiRise (aka HiRise 2.0) for the more lucrative hip and knee surgeries will drive sales, suggest the analysts.

In early-FY25, management placed shares of $11.58m taking the effective cash balance to $18.1m. The company is now funded for FY25 and possibly well beyond, suggests the broker.

The Speculative Buy rating is unchanged, and the broker's target decreased to 26c from 35c.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -6.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CVB STOCK CHART

FNArena News on CVB

1
FNArena Corporate Results Monitor – 06-09-2024

4:05 PM - Australia